STOCK TITAN
  1. Home
  2. News
  3. NVTA

Invitae Corporation - NVTA STOCK NEWS

Welcome to our dedicated page for Invitae Corporation news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on Invitae Corporation stock.

Invitae Corporation (OTC: NVTA) is a prominent medical genetics company based in San Francisco. The firm is on a mission to integrate genetic information into everyday medical practice to enhance healthcare quality for billions worldwide. Invitae specializes in genetic diagnostics for hereditary disorders, enabling clinicians and patients to access comprehensive genetic testing services with higher quality, faster turnaround times, and lower costs compared to traditional single-gene tests. The company offers curated panels and customizable tests, making genetic information more accessible and actionable.

Invitae has pioneered significant advancements in the field, including the recent partnership with BridgeBio Pharma to bolster genetics-based drug discovery for rare diseases. This collaboration aims to uncover new therapeutic targets and deepen insights into genetic modifiers, using Invitae's extensive genetic dataset generated from over 4 million patients.

However, Invitae has faced financial challenges, leading to a voluntary Chapter 11 bankruptcy filing in early 2024. Despite these hurdles, the company remains committed to its vision, continuing operations and focusing on its strategic initiatives to improve healthcare delivery.

Among its innovative projects, Invitae recently launched Clinical Variant Modeling, an AI-driven approach to enhance the clinical interpretation of genetic tests, especially for hereditary cancers like Lynch syndrome. This initiative is expected to reduce the uncertainty in genetic test results, providing more definitive answers and improving patient outcomes.

The company's dedication to leveraging advanced technology and extensive datasets underscores its potential to transform genetic testing and healthcare delivery on a global scale. For more updates and detailed information, visit Invitae's website.

News

Invitae Completes Sale of Reproductive Health Assets to Natera

Rhea-AI Summary
Invitae (NVTA) completes the sale of reproductive health assets to Natera (NTRA) for up to $52.5 million, aiming to focus on clinical germline genetic information and reduce operating expenses by approximately $44 million annually. Natera has hired Invitae reproductive health sales representatives and will take over customer transition for non-invasive prenatal and carrier screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts

Rhea-AI Summary
Invitae (NVTA) divests Ciitizen assets, maintains minority equity stake, and anticipates $90-100 million annual cash savings. The company also implements strategic cost cuts and workforce reduction to streamline operations and reduce cash burn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.36%
Tags
none
-
News

Aranscia Acquires YouScript from Invitae

Rhea-AI Summary
Invitae Corporation: Aranscia acquires select assets of YouScript personalized medication management platform from Invitae Corporation, a leader in medical genetics. YouScript's PGx insights enable healthcare providers to scale personalized medication management programs. YouScript joins Aranscia's portfolio of companies, including 2bPrecise, SinguLab, and AccessDx Laboratory, to democratize precision medicine. Studies show PGx testing with YouScript's technology led to a 71% reduction in hospital emergency visits, 39% reduction in admissions, and $1,132 in estimated cost savings in just four months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
acquisition
News

Invitae Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
NVTA: Invitae Reports $121.2M Q3 Revenue, 9% YoY Decrease; Pro Forma Revenue Up 4%; Gross Margin 32.2%; Reaffirms 2023 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.04%
Tags
earnings
-
News

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships

Rhea-AI Summary
Invitae announces enhanced chemistry of its Invitae Personalized Cancer Monitoring platform to detect circulating tumor DNA (ctDNA) as a biomarker for solid tumor malignancies. The assay features a patient-specific panel design with a sensitivity of >99% for detecting ctDNA at low variant allele frequencies. The company also received CLIA approval for the whole exome sequencing component of PCM as a stand-alone comprehensive genomic profiling assay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
partnership
-
News

Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Rhea-AI Summary
Invitae (NYSE: NVTA) will report its Q3 2023 financial results on November 8, 2023. The conference call and webcast to discuss the results will be held at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Participants can register for the conference call using the provided link. The webcast and slide deck will be available on the company's website. A replay of the webcast will also be archived on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
earnings
News

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

Rhea-AI Summary
Invitae announces findings from the largest study on uncertain results from hereditary disease genetic testing. The study highlights the prevalence of variants of uncertain significance (VUS) and the need for detailed clinical information and family studies for proper interpretation. The study also found that the likelihood of identifying a VUS increased with larger gene panels and varied based on race, ethnicity, and ancestry. Over the course of the study, a large number of VUSs were reclassified, impacting more than 160,000 individuals. Invitae has invested in developing machine learning methods to reduce uncertainty in genetic testing results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
News

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

Rhea-AI Summary
Invitae appoints David Sholehvar as Chief Operating Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
management
-
News

Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer

Rhea-AI Summary
Invitae announces results of collaborative study on universal hereditary cancer genetic testing in breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
News

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

Rhea-AI Summary
Invitae showcases research at NSGC conference and presents Heart of Genetic Counseling Award
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.73%
Tags
conferences

FAQ

What is the market cap of Invitae Corporation (NVTA)?

The market cap of Invitae Corporation (NVTA) is approximately 5.6M.

What does Invitae Corporation specialize in?

Invitae specializes in genetic diagnostics for hereditary disorders, providing comprehensive genetic testing services.

What is the mission of Invitae Corporation?

Invitae aims to integrate genetic information into routine medical practice to improve healthcare quality for billions of people.

What recent partnerships has Invitae announced?

Invitae recently partnered with BridgeBio Pharma to advance genetics-based drug discovery for rare diseases.

What financial challenges is Invitae facing?

Invitae has filed for voluntary Chapter 11 bankruptcy to restructure its debts and improve its financial condition.

What is Clinical Variant Modeling?

Clinical Variant Modeling is an AI-driven approach launched by Invitae to enhance the interpretation of genetic test results and reduce uncertainty.

How extensive is Invitae's genetic dataset?

Invitae's genetic dataset includes information from over 4 million patients, providing a rich resource for genetic research and diagnostics.

Who recently acquired Invitae's assets?

Labcorp has been selected as the winning bidder to acquire Invitae's assets as part of the company's financial restructuring.

How does Invitae's partnership with BridgeBio Pharma benefit rare disease research?

The partnership aims to combine genetic data and expertise to discover new therapeutic targets and advance research in rare diseases.

What role does AI play in Invitae's genetic testing services?

AI is used to improve the accuracy and efficiency of genetic test result interpretation, reducing variants of uncertain significance and providing clearer answers.

How does Invitae support healthcare professionals and patients?

Invitae provides accurate, timely genetic information to support medical decision-making, helping clinicians and patients manage hereditary conditions effectively.

Stock NVTA logo
Invitae Corporation

NYSE:NVTA

NVTA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NVTA Stock Data

5.59M
284.38M
1.51%
47.96%
23.65%
Diagnostics & Research
Healthcare
Link
United States
San Francisco